Prostate Cancer Mortality Benefit Seen for Family History-Based Screening

Share this content:
Screening white men with a family history of prostate cancer appears to be associated with a decrease in prostate cancer-specific mortality.
Screening white men with a family history of prostate cancer appears to be associated with a decrease in prostate cancer-specific mortality.

Screening white men with a family history of prostate cancer appears to be associated with a decrease in prostate cancer-specific mortality, according to a study published in The Journal of Urology.

Michael A. Liss, M.D., from the University of California-San Diego Health System, and colleagues used data from the PLCO (Prostate, Lung, Colorectal and Ovarian) cancer screening trial to compare prostate cancer-specific mortality in the screening and usual care arms of men with and without family history of prostate cancer.

Data were included for 65,179 white subjects, of whom 11.2 percent were diagnosed with prostate cancer and 7.4 percent had a family history of prostate cancer.

The researchers found that positive family history correlated with significantly increased incidence of prostate cancer (16.9 versus 10.8 percent; P < 0.01) and prostate cancer-specific mortality (0.56 versus 0.37 percent; P < 0.01), with a trend toward significance after multivariate adjustment (hazard ratio, 1.47; 95 percent confidence interval, 0.98 to 2.21; P = 0.06).

RELATED: Five-Year Follow Up Data: Receiving Active Surveillance for Prostate Cancer

In men with a positive family history, screening correlated with a trend toward decreased prostate cancer-specific mortality (hazard ratio, 0.49; 95 percent confidence interval, 0.22 to 1.1; P = 0.08) and with decreased time to prostate cancer death (log rank P = 0.05).

"With these promising data it may be more prudent to focus screening efforts on high-risk groups such as those with a positive family history, and possibly even black men and others with a genetic predisposition rather than abandoning them in general as suggested by the U.S. Preventive Services Task Force," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries.

Reference

  1. Liss, Michael A., et al. "Impact of Family History on Prostate Cancer Mortality in White Men Undergoing Prostate Specific Antigen Based Screening." The Journal of Urology. DOI: dx.doi.org/10.1016/j.juro.2014.07.085. July 24, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters